136 related articles for article (PubMed ID: 26799363)
1. Bullous pemphigoid suggestive of complement-independent blister formation with anti-BP180 IgG4 autoantibodies.
Dainichi T; Nishie W; Yamagami Y; Sonobe H; Ujiie H; Kaku Y; Kabashima K
Br J Dermatol; 2016 Jul; 175(1):187-90. PubMed ID: 26799363
[No Abstract] [Full Text] [Related]
2. Bullous pemphigoid autoantibodies directly induce blister formation without complement activation.
Ujiie H; Sasaoka T; Izumi K; Nishie W; Shinkuma S; Natsuga K; Nakamura H; Shibaki A; Shimizu H
J Immunol; 2014 Nov; 193(9):4415-28. PubMed ID: 25261486
[TBL] [Abstract][Full Text] [Related]
3. IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid.
Dainichi T; Chow Z; Kabashima K
J Dermatol Sci; 2017 Dec; 88(3):265-270. PubMed ID: 28747266
[TBL] [Abstract][Full Text] [Related]
4. Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida.
Iwata H; Kitajima Y
Exp Dermatol; 2013 Jun; 22(6):381-5. PubMed ID: 23651418
[TBL] [Abstract][Full Text] [Related]
5. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
[TBL] [Abstract][Full Text] [Related]
6. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
7. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.
Kromminga A; Scheckenbach C; Georgi M; Hagel C; Arndt R; Christophers E; Bröcker EB; Zillikens D
J Autoimmun; 2000 Nov; 15(3):293-300. PubMed ID: 11040070
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of bullous pemphigoid.
Ujiie H; Nishie W; Shimizu H
Immunol Allergy Clin North Am; 2012 May; 32(2):207-15, v. PubMed ID: 22560134
[TBL] [Abstract][Full Text] [Related]
9. Complement and cutaneous autoimmune blistering diseases.
Lessey E; Li N; Diaz L; Liu Z
Immunol Res; 2008; 41(3):223-32. PubMed ID: 18641925
[TBL] [Abstract][Full Text] [Related]
10. IgG4 autoantibodies induce dermal-epidermal separation.
Mihai S; Chiriac MT; Herrero-González JE; Goodall M; Jefferis R; Savage CO; Zillikens D; Sitaru C
J Cell Mol Med; 2007; 11(5):1117-28. PubMed ID: 17979887
[TBL] [Abstract][Full Text] [Related]
11. Biochip detection of BP180 autoantibodies in blister fluid for the serodiagnosis of bullous pemphigoid: A pilot study.
Sernicola A; Russo I; Saponeri A; Alaibac M
Medicine (Baltimore); 2019 Feb; 98(7):e14514. PubMed ID: 30762788
[TBL] [Abstract][Full Text] [Related]
12. What's new in bullous pemphigoid.
Ujiie H; Shibaki A; Nishie W; Shimizu H
J Dermatol; 2010 Mar; 37(3):194-204. PubMed ID: 20507382
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes.
Schmidt E; Reimer S; Kruse N; Jainta S; Bröcker EB; Marinkovich MP; Giudice GJ; Zillikens D
J Invest Dermatol; 2000 Nov; 115(5):842-8. PubMed ID: 11069622
[TBL] [Abstract][Full Text] [Related]
14. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230.
Skaria M; Jaunin F; Hunziker T; Riou S; Schumann H; Bruckner-Tuderman L; Hertl M; Bernard P; Saurat JH; Favre B; Borradori L
J Invest Dermatol; 2000 May; 114(5):998-1004. PubMed ID: 10771483
[TBL] [Abstract][Full Text] [Related]
15. Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms.
Cole C; Vinay K; Borradori L; Amber KT
Front Immunol; 2022; 13():912876. PubMed ID: 35874745
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin G subclass distribution of bullous pemphigoid autoantibodies and complement fixation studies.
Al-Karawi KS
Saudi Med J; 2002 Dec; 23(12):1492-5. PubMed ID: 12518199
[TBL] [Abstract][Full Text] [Related]
17. A case of levetiracetam induced bullous pemphigoid.
Karadag AS; Bilgili SG; Calka O; Onder S; Kosem M; Burakgazi-Dalkilic E
Cutan Ocul Toxicol; 2013 Jun; 32(2):176-8. PubMed ID: 23030621
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid.
Shimanovich I; Mihai S; Oostingh GJ; Ilenchuk TT; Bröcker EB; Opdenakker G; Zillikens D; Sitaru C
J Pathol; 2004 Dec; 204(5):519-27. PubMed ID: 15538734
[TBL] [Abstract][Full Text] [Related]
19. Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation.
Engineer L; Bhol K; Kumari S; Razzaque Ahmed A
Cytokine; 2001 Jan; 13(1):32-38. PubMed ID: 11145840
[TBL] [Abstract][Full Text] [Related]
20. Are anti-BP180 IgG1 or IgG4 autoantibodies pathogenic?
Liu Z
J Invest Dermatol; 2002 Nov; 119(5):989-90. PubMed ID: 12445182
[No Abstract] [Full Text] [Related]
[Next] [New Search]
